Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Issues related to symptomatic and disease‐modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy

Open access
Brooks‐Kayal, Amy R., Bath, Kevin G., Berg, Anne T., Galanopoulou, Aristea S., Holmes, Gregory L., Jensen, Frances E., Kanner, Andres M., O'Brien, Terence J., Whittemore, Vicky H., Winawer, Melodie R., Patel, Manisha, Scharfman, Helen E.·2013·Epilepsia

Abstract

Summary: Many symptoms of neurologic or psychiatric illness—such as cognitive impairment, depression, anxiety, attention deficits, and migraine—occur more frequently in people with epilepsy than in the general population. These diverse comorbidities present an underappreciated problem for people with epilepsy and their caregivers because they decrease quality of life, complicate treatment, and increase mortality. In fact, it has been suggested that comorbidities can have a greater effect on quality of life in people with epilepsy than the seizures themselves. There is increasing recognition of the frequency and impact of cognitive and behavioral comorbidities of epilepsy, highlighted in the 2012 I nstitute of M edicine report on epilepsy. Comorbidities have also been acknowledged, as a National Institutes of Health (NIH) B enchmark area for research in epilepsy. However, relatively little progress has been made in developing new therapies directed specifically at comorbidities. On the other hand, there have been many advances in understanding underlying mechanisms. These advances have made it possible to identify novel targets for therapy and prevention. As part of the I nternational L eague A gainst E pilepsy/A merican E pilepsy S ociety workshop on preclinical therapy development for epilepsy, our working group considered the current state of understanding related to terminology, models, and strategies for therapy development for the comorbidities of epilepsy. Herein we summarize our findings and suggest ways to accelerate development of new therapies. We also consider important issues to improve research including those related to methodology, nonpharmacologic therapies, biomarkers, and infrastructure.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/epi.12298

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 167

Metadata

Authors
Brooks‐Kayal, A. R., Bath, K. G., Berg, A. T., Galanopoulou, A. S., Holmes, G. L., Jensen, F. E., Kanner, A. M., O'Brien, T. J., Whittemore, V. H., Winawer, M. R., Patel, M., & Scharfman, H. E.
Venue
Epilepsia
Publisher
Wiley
Published
2013-08
Volume
54
Issue
s4
Pages
44-60
ISSN
  • 0013-9580 (ISSN-L)
  • 1528-1167
OpenAlex
W2160223635
Cited by
167
References
16
FWCI
12.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Issues related to symptomatic and disease‐modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy. https://app.cochat.ai/papers/10.1111/epi.12298
The paper
Brooks‐Kayal, A. R., Bath, K. G., Berg, A. T., Galanopoulou, A. S., Holmes, G. L., Jensen, F. E., Kanner, A. M., O'Brien, T. J., Whittemore, V. H., Winawer, M. R., Patel, M., & Scharfman, H. E. (2013). Issues related to symptomatic and disease‐modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy. Epilepsia. https://doi.org/10.1111/epi.12298

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.